Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266265 · ClinicalTrials.gov registry record
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A clinical trial of Pulmonary Arterial Hypertension, sponsored by United Therapeutics.
- Completed
- Registry status
- 1,333
- Enrollment target
- 20
- Study locations
NCT01266265 is a study of Pulmonary Arterial Hypertension that has completed, run by United Therapeutics. The registered enrollment target is 1,333 participants, above the 441-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (202% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT01266265, a study of Pulmonary Arterial Hypertension, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- 1,333 participants
- Enrollment target
- 20
- Study locations
Study Summary
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
Conditions Studied
Interventions
- DRUG inhaled prostacyclin
- DRUG prostacyclin
- DRUG subcutaneous and intravenous prostacyclin
- DRUG oral ERA
Study Locations (20)
California
- Berkeley Cardiovascular Medical Group - Berkeley
- Cedars-Sinai Heart Institute - Beverly Hills
- University California San Francisco - Fresno
- University of Southern California - Los Angeles
- West Los Angeles VA Healthcare Center - Los Angeles
- University of California Davis Medical Center - Sacramento
- University of California, San Francisco - San Francisco
- Paloma Medical Group - San Juan Capistrano
- Santa Barbara Cottage Hospital - Santa Barbara
- Stanford Hospital and Clinics - Stanford
Florida
- St. Francis Sleep Allergy & Lung - Clearwater
- University of Florida - Gainesville
- Pulmonary and Critical Care Associates - Jacksonville
- University of Florida College of Medicine Jacksonville - Jacksonville
Alabama
- Cardiovascular Associates, P.C. - Birmingham
- The University of Alabama at Birmingham - Birmingham
- University of South Alabama - Mobile
Colorado
- Children's Hospital Denver - Denver
- Western States Clinical Research, Inc. - Wheat Ridge
Arizona
- Arizona Pulmonary Specialists, LTD - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,333 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01266265
The ClinicalTrials.gov registry entry for NCT01266265 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,333 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 441-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (202% higher). The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 4 interventions - of which inhaled prostacyclin is the first listed.
NCT01266265 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01266265 about?
NCT01266265 is a clinical study titled "Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies". A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
What is the current status of trial NCT01266265?
This trial is currently completed. The enrollment target is 1,333 participants. The study started on 2010-12. Estimated completion is 2014-12.
What conditions does trial NCT01266265 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT01266265?
The interventions under investigation include: inhaled prostacyclin (DRUG), prostacyclin (DRUG), subcutaneous and intravenous prostacyclin (DRUG), oral ERA (DRUG).
Who is sponsoring clinical trial NCT01266265?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01266265 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.